前列腺癌是严重危害全世界老年男性健康的恶性肿瘤。近年来我国前列腺癌的发病率迅速上升，已成为影响老年男性健康的主要泌尿系统恶性肿瘤。前列腺特异性膜抗原（PSMA）正电子发射计算机断层显像/计算机断层扫描（PET/CT）作为一种新型的诊疗手段，因其特异性的显像效果及病灶高浓聚优势，受到了泌尿外科临床医师的关注及追捧。采用诊断性核素⁶⁸Ga标记的PSMA PET/CT对前列腺癌的早期诊断和预后评估起到积极的作用。此外，治疗性核素¹⁷⁷Lu标记的PSMA PET/CT能够一定程度上抑制前列腺癌的生长，尤其适用于高危前列腺癌患者。作者综合上述研究，对⁶⁸Ga-PSMA和¹⁷⁷Lu-PSMA在淋巴结转移的高危前列腺癌诊疗一体化中的研究进展进行综述。

[1] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012[J].Int J Cancer, 2015, 136(5):E359-386.
[2] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2018, 68(6):394-424.
[3] 韩苏军, 张思维, 马建辉, 等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤杂志, 2013, 18:330-334.
[4] LI R, RAVIZZINI G C, GORIN M A, et al. The use of PET/CT in prostate cancer[J].Prostate Cancer Prostatic Dis, 2018, 21(1):4-21.
[5] PERERA M, PAPA N, CHRISTIDIS D, et al. Sensitivity, specificity, and predictors of positive ⁶⁸Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer:a systematic review and meta-analysis[J].Eur Urol, 2016, 70(6):926-937.
[6] RAHBAR K, AHMADZADEHFAR H, SEIFERT R, et al.[177 Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer[J].Lancet Oncol, 2018, 19(8):e371.
[7] FREITAG M T, RADTKE J P, HADASCHIK B A, et al. Comparison of hybrid ⁶⁸Ga-PSMA PET/MRI and ⁶⁸Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer[J].Eur J Nucl Med Mol Imaging, 2016, 43(1):70-83.
[8] WRIGHT G L, HALEY C, BECKETT M L, et al. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues[J].Urol Oncol, 1995, 1(1):18-28.
[9] SOKOLOFF R L, NORTON K C, GASIOR C L, et al. A dual-monoclonal sandwich assay for prostate-specific membrane antigen:levels in tissues,seminal fluid and urine[J].Prostate, 2000, 43(2):150-157.
[10] GHOSH A, HESTON W D. Tumor target prostate specific membrane antigen(PSMA) and its regulation in prostate cancer[J].J Cell Biochem, 2004, 91(3):528-539.
[11] FUNG E K, CHEAL S M, FAREEDY S B, et al. Targeting of radiolabeled J591 antibody to PSMA-expressing tumors:optimization of imaging and therapy based on non-linear compartmental modeling[J].EJNMMI Res, 2016, 6(1):7.
[12] HÖVELS A M, HEESAKKERS R A, ADANG E M, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer:a meta-analysis[J].Clin Radiol, 2008, 63(4):387-395.
[13] MEASE R C, FOSS C A, POMPER M G. PET imaging in prostate cancer:focus on prostate-specific membrane antigen[J].Curr Top Med Chem, 2013, 13(8):951-962.
[14] SWEAT S D, PACELLI A, MURPHY G P, et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases[J].Urology, 1998, 52(4):637-640.
[15] 王静楠,臧洁,李方, 等.靶向前列腺特异性膜抗原的核医学精准诊疗进展[J].现代仪器与医疗, 2018, 24(6):1-7.
[16] AFSHAR-OROMIEH A, HABERKORN U, EDER M, et al.[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer:comparison with 18F-FECH[J].Eur J Nucl Med Mol Imaging, 2012, 39(6):1085-1086.
[17] FERRARO D A, MUEHLEMATTER U J, GARCIA-SCHVLER H I, et al. ⁶⁸Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer[J].Eur J Nucl Med Mol Imaging, 2020, 47(1):147-159.
[18] ZANG S, SHAO G, CUI C, et al. ⁶⁸Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients[J].Oncotarget, 2017, 8(7):12247-12258.
[19] TULSYAN S, DAS C J, TRIPATHI M, et al. Comparison of ⁶⁸Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer ⁶⁸Ga-PSMA PET and MRI in prostate cancer[J].Nucl Med Commun, 2017, 38(12):1094-1102.
[20] ZHANG Q, ZANG S, ZHANG C, et al. Comparison of ⁶⁸Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer[J].J Transl Med, 2017, 15(1):230.
[21] RAHBAR K, SCHMIDT M, HEINZEL A, et al. Response and tolerability of a single dose of ¹⁷⁷Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer:a multicenter retrospective analysis[J].J Nucl Med, 2016, 57(9):1334-1338.
[22] EDLER VON EYBEN F, SINGH A, ZHANG J, et al. ¹⁷⁷Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer[J].Oncotarget, 2019, 10(25):2451-2461.
[23] WEINEISEN M, SCHOTTELIUS M, SIMECEK J, et al. ⁶⁸Ga- and ¹⁷⁷Lu-Labeled PSMA I & T:Optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies[J]. J Nucl Med, 2015, 56(8):1169-1176.
[24] MAFFEY-STEFFAN J, SCARPA L, SVIRYDENKA A, et al. The ⁶⁸Ga/¹⁷⁷Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer:impact of post-therapeutic whole-body scintigraphy in the follow-up[J].Eur J Nucl Med Mol Imaging, 2019, 47(3):695-712.